基于马赛克HA序列的H9亚型禽流感灭活疫苗的免疫效力分析

doi:10.11843/j.issn.0366-6964.2021.012.023

畜牧兽医学报 ›› 2021, Vol. 52 ›› Issue (12): 3569-3577.doi: 10.11843/j.issn.0366-6964.2021.012.023

基于马赛克HA序列的H9亚型禽流感灭活疫苗的免疫效力分析

李丽¹, 唐国毅¹, 冯贺龙¹, 薛玉涵¹, 任助¹, 王国康¹, 贾妙妙¹, 商雨^1,2,3, 罗青平^1,2,3, 邵华斌^1,2,3, 温国元^1,2,3*

1. 湖北省农业科学院畜牧兽医研究所, 武汉 430064;
2. 农业部畜禽细菌病防治制剂创制重点实验室, 武汉 430064;
3. 畜禽病原微生物学湖北省重点实验室, 武汉 430064

收稿日期:2021-03-16 出版日期:2021-12-25 发布日期:2021-12-22
通讯作者: 温国元,主要从事新城疫病毒耐热分子机制及新型疫苗研发等研究,E-mail:wgy_524@163.com
作者简介:李丽(1987-)女,河南南阳人,助理研究员,主要从事新城疫病毒分子生物学等相关研究,E-mail:734267021@qq.com
基金资助:
国家重点研发计划（2017YFD0501104；2016YFD0500202）；国家现代农业产业技术体系建设专项资金（CARS-43-G13）；湖北省农业科学院领军人才项目（L2018019）

Evaluation of Immune Efficacy of H9 Subtype Avian Influenza Virus Inactivated Vaccine Based on Mosaic HA Sequence

LI Li¹, TANG Guoyi¹, FENG Helong¹, XUE Yuhan¹, REN Zhu¹, WANG Guokang¹, JIA Miaomiao¹, SHANG Yu^1,2,3, LUO Qingping^1,2,3, SHAO Huabin^1,2,3, WEN Guoyuan^1,2,3*

1. Institute of Animal Husbandry and Veterinary Sciences, Hubei Academy of Agricultural Sciences, Wuhan 430064, China;
2. Key Laboratory of Prevention and Control Agents for Animal Bacteriosis (Ministry of Agriculture), Wuhan 430064, China;
3. Hubei Provincial Key Laboratory of Livestock and Poultry Pathogen Microbiology, Wuhan 430064, China

Received:2021-03-16 Online:2021-12-25 Published:2021-12-22

摘要/Abstract

摘要： H9亚型禽流感在我国家禽中广泛流行，给养禽业造成巨大经济损失的同时，也严重威胁着公共卫生安全。H9亚型禽流感病毒（avian influenza virus，AIV）具有高度遗传变异性，导致流行株和疫苗株之间抗原匹配性差，从而影响疫苗的临床保护效果，急需研发一种高效、具有交叉保护性的通用型H9亚型禽流感疫苗。马赛克疫苗是针对遗传多样性病原体设计，通过整合所有抗原序列获得一条抗原表位覆盖最广泛的嵌合蛋白，并制备疫苗。本研究参考mosaic疫苗设计原则，设计、优化并合成了一条H9亚型禽流感病毒的mosaic血凝素（hemagglutinin，HA）基因序列，采用反向遗传操作技术，以H1N1亚型流感病毒PR8株为骨架，以mosaic H9HA序列替换PR8株的HA片段，获得重组病毒rPR8-HAm/H9。将其制备为灭活疫苗并免疫SPF雏鸡，监测抗体水平、攻毒保护效果，评价其交叉保护效果。结果表明，重组病毒rPR8-HAm/H9灭活疫苗免疫SPF雏鸡，可诱导机体产生较高水平的HI抗体和中和抗体，可显著抑制攻毒后病毒的脱落，对H9N2 AIV JM0305株的攻毒保护率为80%。rPR8-HAm/H9灭活疫苗可以对异源H9N2 AIV JM0305株产生较好的交叉攻毒保护，为研发基于马赛克技术的禽流感通用疫苗提供了前期基础。

关键词: 禽流感病毒, H9亚型, mosaic疫苗, 交叉保护性

Abstract: H9 subtype avian influenza is widely prevalent in poultry in China, which has caused huge economic losses to the poultry industry and also seriously threatened the public health safety. The high genetic variability of H9 subtype avian influenza virus (AIV) leads to poor antigenic matching between the circulating and vaccine strains, thus affecting the clinical protective effect of the vaccine. Therefore, it is urgent to develop a highly effective cross-protective vaccine against H9 subtype AIV. Mosaic vaccine is designed for the genetic diversity of pathogens by integrating all antigenic sequences to obtain a mosaic protein with the most extensive epitopes coverage, and to generate vaccine. In order to develop an efficient and universal H9 subtype avian influenza vaccine, a mosaic HA sequence of H9 AIV HAm/H9 was designed, optimized and synthesized according to the principles of mosaic vaccine. Utilizing the reverse genetic technology, a recombinant virus rPR8-HAm/H9 was constructed and rescued by replacing the HA segment of influenza virus PR8 strain (H1N1) with the HAm/H9 gene. The SPF chickens were immunized with the inactivated rPR8-HAm/H9 virus, and the effect of cross-protection was evaluated by detecting the antibody titer, the protection rate and viral shedding. The recombinant virus rPR8-HAm/H9 could induce high level of HI antibody and neutralizing antibody, as well as reduce virus shedding, and the protection rate against H9N2 AIV JM0305 strain was 80%. Our results showed that rPR8-HAm/H9 inactivated vaccine could provide efficient cross-protection against H9N2 AIV strain JM0305, and provided a preliminary basis for the research and development of universal vaccine for avian influenza based on mosaic technology.

Key words: avian influenza virus, H9 subtype, mosaic vaccine, cross protection

中图分类号:

S858.315.3

李丽, 唐国毅, 冯贺龙, 薛玉涵, 任助, 王国康, 贾妙妙, 商雨, 罗青平, 邵华斌, 温国元. 基于马赛克HA序列的H9亚型禽流感灭活疫苗的免疫效力分析[J]. 畜牧兽医学报, 2021, 52(12): 3569-3577.

LI Li, TANG Guoyi, FENG Helong, XUE Yuhan, REN Zhu, WANG Guokang, JIA Miaomiao, SHANG Yu, LUO Qingping, SHAO Huabin, WEN Guoyuan. Evaluation of Immune Efficacy of H9 Subtype Avian Influenza Virus Inactivated Vaccine Based on Mosaic HA Sequence[J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(12): 3569-3577.

参考文献 30

[1]	BISWAS P K, CHRISTENSEN J P, AHMED S S U, et al. Avian influenza outbreaks in chickens, Bangladesh[J]. Emerg Infect Dis, 2008, 14(12):1909-1912.
[2]	DUCATEZ M F, WEBSTER R G, WEBBY R J. Animal influenza epidemiology[J]. Vaccine, 2008, 26(S4):D67-D69.
[3]	NAGARAJAN S, RAJUKUMAR K, TOSH C, et al. Isolation and pathotyping of H9N2 avian influenza viruses in Indian poultry[J]. Vet Microbiol, 2009, 133(1-2):154-163.
[4]	PEACOCK T, REDDY K, JAMES J, et al. Antigenic mapping of an H9N2 avian influenza virus reveals two discrete antigenic sites and a novel mechanism of immune escape[J]. Sci Rep, 2016, 6(1):18745.
[5]	ZHANG S X, YU J L, HE L, et al. Molecular characteristics of the H9N2 avian influenza viruses in live poultry markets in Anhui Province, China, 2013 to 2018[J]. Health Sci Rep, 2021, 4(1):e230.
[6]	LU J H, LIU X F, SHAO W X, et al. Phylogenetic analysis of eight genes of H9N2 subtype influenza virus:a Mainland China strain possessing early isolates' genes that have been circulating[J]. Virus Genes, 2005, 31(2):163-169.
[7]	XU K M, SMITH G J D, BAHL J, et al. The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005[J]. J Virol, 2007, 81(19):10389-10401.
[8]	FUSARO A, MONNE I, SALVIATO A, et al. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications[J]. J Virol, 2011, 85(16):8413-8421.
[9]	LIU H Q, LIU X F, CHENG J, et al. Phylogenetic analysis of the hemagglutinin genes of twenty-six avian influenza viruses of subtype H9N2 isolated from chickens in China during 1996-2001[J]. Avian Dis, 2003, 47(1):116-127.
[10]	SUN Y P, LIU J H. H9N2 influenza virus in China:a cause of concern[J]. Protein Cell, 2015, 6(1):18-25.
[11]	丛彦龙, 钟颖, 孙艺学, 等. H9N2亚型禽流感病毒流行病学及其疫苗的研究进展[J]. 中国兽医学报, 2017, 37(2):386-392.CONG Y L. ZHONG Y. SUN Y X, et al. Advance on epidemiology and vaccine of H9N2 avian influenza virus[J]. Chinese Journal of Veterinary Science, 2017, 37(2):386-392. (in Chinese)
[12]	ZHANG P H, TANG Y H, LIU X W, et al. Characterization of H9N2 influenza viruses isolated from vaccinated flocks in an integrated broiler chicken operation in eastern China during a 5 year period (1998-2002)[J]. J Gen Virol, 2008, 89(12):3102-3112.
[13]	PARK K J, KWON H I, SONG M S, et al. Rapid evolution of low-pathogenic H9N2 avian influenza viruses following poultry vaccination programmes[J]. J Gen Virol, 2011, 92(1):36-50.
[14]	SUN Y P, PU J, FAN L H, et al. Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens[J]. Vet Microbiol, 2012, 156(1-2):193-199.
[15]	SUN Y P, BI Y H, PU J, et al. Guinea pig model for evaluating the potential public health risk of swine and avian influenza viruses[J]. PLoS One, 2010, 5(11):e15537.
[16]	KINGSTAD-BAKKE B A, CHANDRASEKAR S S, PHANSE Y, et al. Effective mosaic-based nanovaccines against avian influenza in poultry[J]. Vaccine, 2019, 37(35):5051-5058.
[17]	BAROUCH D H, O'BRIEN K L, SIMMONS N L, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys[J]. Nat Med, 2010, 16(3):319-323.
[18]	FISCHER W, PERKINS S, THEILER J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants[J]. Nat Med, 2007, 13(1):100-106.
[19]	GOGOLÁK P, SIMON Á, HORVÁTH A, et al. Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin[J]. Biochem Biophys Res Commun, 2000, 270(1):190-198.
[20]	LI Y, LIU M D, SUN Q Q, et al. Genotypic evolution and epidemiological characteristics of H9N2 influenza virus in Shandong Province, China[J]. Poult Sci, 2019, 98(9):3488-3495.
[21]	SUAREZ D L, SENNE D A, BANKS J, et al. Recombination resulting in virulence shift in avian influenza outbreak, Chile[J]. Emerg Infect Dis, 2004, 10(4):693-699.
[22]	MONNE I, FUSARO A, NELSON M I, et al. Emergence of a highly pathogenic avian influenza virus from a low-pathogenic progenitor[J]. J Virol, 2014, 88(8):4375-4388.
[23]	READ A F, BAIGENT S J, POWERS C, et al. Imperfect vaccination can enhance the transmission of highly virulent pathogens[J]. PLoS Biol, 2015, 13(7):e1002198.
[24]	LEE D H, FUSARO A, SONG C S, et al. Poultry vaccination directed evolution of H9N2 low pathogenicity avian influenza viruses in Korea[J]. Virology, 2016, 488:225-231.
[25]	孙华鹏, 崔新鑫, 潘亮奇, 等. 中国H9N2亚型禽流感病毒的流行现状[J]. 畜牧兽医学报, 2021, 52(5):1218-1229.SUN H P, CUI X X, PAN L Q, et al. The Epidemiology of H9N2 Avian Influenza Virus in China[J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(5):1218-1229.(in Chinese)
[26]	ZOU C C, MURAKOSHI H, KUSE N, et al. Effective suppression of HIV-1 replication by cytotoxic T lymphocytes specific for Pol epitopes in conserved mosaic vaccine immunogens[J]. J Virol, 2019, 93(7):e02142-18.
[27]	LIU M K P, HAWKINS N, RITCHIE A J, et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape[J]. J Clin Invest, 2012, 123(1):380-393.
[28]	KAMLANGDEE A, KINGSTAD-BAKKE B, ANDERSON T K, et al. Broad protection against avian influenza virus by using a modified Vaccinia ankara virus expressing a mosaic Hemagglutinin gene[J]. J Virol, 2014, 88(22):13300-13309.
[29]	KAMLANGDEE A, KINGSTAD-BAKKE B, OSORIO J E, et al. Mosaic H5 Hemagglutinin provides broad Humoral and cellular immune responses against influenza viruses[J]. J Virol, 2016, 90(15):6771-6783.
[30]	FLOREK N W, KAMLANGDEE A, MUTSCHLER J P, et al. A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques[J]. PLoS One, 2017, 12(8):e0181738.

基于马赛克HA序列的H9亚型禽流感灭活疫苗的免疫效力分析

Evaluation of Immune Efficacy of H9 Subtype Avian Influenza Virus Inactivated Vaccine Based on Mosaic HA Sequence

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨芷翊, 王新凯, 史玉婷, 付思源, 张钰炘, 曹琛福, 贾伟新. 基于RT-RAA的禽流感H5亚型核酸CRISPR-Cas13a检测方法的建立[J]. 畜牧兽医学报, 2023, 54(9): 3803-3811.
[2]	周勇, 李知新, 鲁宏伟, 孙燕, 李甜, 杜凡姝, 蒲娟. 我国H5和H7N9亚型高致病性禽流感的监测及疫情暴发分析[J]. 畜牧兽医学报, 2022, 53(9): 3093-3106.
[3]	崔明仙, 王星博, 黄彦铭, 卞希一, 冯梦珂, 颜焰, 董伟仁, 周继勇. 3株H3N2亚型禽流感病毒的基因组特征与演化分析[J]. 畜牧兽医学报, 2022, 53(11): 4116-4122.
[4]	杨洋, 谢黎卿, 胡沛, 高丽旭, 袁祥, 李攀, 彭远义, 李能章. 牛源A型多杀性巴氏杆菌hyaD基因缺失株的构建及其在小鼠上的交叉保护性分析[J]. 畜牧兽医学报, 2022, 53(10): 3582-3597.
[5]	孙华鹏, 崔新鑫, 潘亮奇, 许丰祥, 李硕, 吴梅花, 朱旭辉, 于亚南, 李明亮, 刘杨, 瞿孝云, 廖明, 孙海亮. 中国H9N2亚型禽流感病毒的流行现状[J]. 畜牧兽医学报, 2021, 52(5): 1218-1229.
[6]	李静云, 连朋敬, 白玉, 奚柳青, 张子卉, 牛小飞, 杨俊琦, 乔健. H9N2亚型禽流感病毒感染对小鼠肠道菌群的影响[J]. 畜牧兽医学报, 2021, 52(5): 1359-1368.
[7]	王素春, 仲焕香, 姜楠, 姜利建, 潘子豪, 孙福亮, 刘华雷, 黄保续, 王楷宬. H5、H7和H9亚型禽流感病毒四重荧光RT-PCR检测方法的建立与应用[J]. 畜牧兽医学报, 2020, 51(6): 1429-1437.
[8]	赵冰倩, 罗畅, 刘健新, 李慧子, 张彭涛, 于相龙, 刘博洋, 宁章勇. 连翘水提液体外对禽流感病毒增殖及炎症因子表达的抑制效应[J]. 畜牧兽医学报, 2020, 51(6): 1466-1474.
[9]	申松玮, 王泽源, 范威峰, 祝常椿, 陆游, 石宝兰, 刘雷, 沈海峰, 焦库华, 秦涛, 陈素娟, 彭大新, 刘秀梵. 2017-2018年华东地区H9亚型禽流感病毒分离毒株的抗原差异分析[J]. 畜牧兽医学报, 2019, 50(6): 1230-1238.
[10]	何世成, 彭志, 王卫国, 唐小明, 鲁杏华, 林源, 邓国华, 王昌建. 2011-2015年环洞庭湖区H3亚型禽流感病毒的分离鉴定与遗传演化[J]. 畜牧兽医学报, 2019, 50(2): 382-389.
[11]	高照, 胡娇, 刘秀梵. 两株小鼠致病性差异显著的H5N1禽流感病毒PA蛋白差异互作宿主蛋白研究[J]. 畜牧兽医学报, 2018, 49(9): 1952-1960.
[12]	蒋大秀, 马静, 王晓泉, 胡顺林, 刘晓文, 刘秀梵. 2016-2017年华东地区活禽市场7株H9N2禽流感病毒遗传进化分析[J]. 畜牧兽医学报, 2018, 49(8): 1789-1796.
[13]	谢军, 孙英杰, 周昌娈, 朱善元, 丁铲, 柏家林. 禽流感病毒H9N2与新城疫病毒在鸡成纤维细胞中共感染对病毒复制的影响[J]. 畜牧兽医学报, 2018, 49(11): 2521-2528.
[14]	黄艳艳, 李悦, 张琳, 王进圣, 吴福杰, 吴家强, 刘思当. 6株H9N2亚型禽流感病毒的分子演化和抗原变异分析[J]. 畜牧兽医学报, 2018, 49(10): 2205-2214.
[15]	周佩娇, 邢利, 贾伟新, 廖明. 4株H5N6亚型禽流感病毒毒株的分离鉴定与致病性研究[J]. 畜牧兽医学报, 2018, 49(1): 147-156.